Фармакоэкономический прогноз длительной терапии акатинолом (мемантином) болезни Альцгеймера

Любов Евгений Борисович · Социальная и клиническая психиатрия · 2011

Pharmacoeconomic modeling of a 5-year akatinol (memantine) medication of moderate to severe Alzheimer patients point to superiority of akatinol to standard (conventional) treatments used in regular psychiatric practice because these patients show lower risk of hospitalization or placement to a psychoneurological residential facility. Sensitive analysis emphasizes the dependence of the modeling results on the bed turnover parameter and the percentage of patients in residential nursing facilities.

Cited by 0 works.

Authors